PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial hypercholesterolemia (FH ...

Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780 ... therapy in treatment-naive participants with high cholesterol (hypercholesterolaemia).

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

PCSK9 inhibitors are generally recommended for patients with a family history of high cholesterol.” Dr. Quevedo adds that drugs like semaglutide can reduce the risk of heart disease in people ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

The Indian government has decided to exempt customs duty on 36 life-saving drugs to enhance access to essential treatments ...